Medpace Holdings Inc 's ROA from the third quarter of 2026 to the third quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Medpace Holdings Inc 's ROA in the third quarter of 2026?
Medpace Holdings Inc achieved a return on average assets (ROA) of 24.33 % in its third quarter of 2026, this is above MEDP's average return on assets of 13.98%.
Medpace Holdings Inc s assets during the 12 months ending in the third quarter of 2026 are valued at $2 billion

ROA fell compared to the second quarter of 2026, despite the net income growth of 13.26% from the second quarter of 2026.

However, within the Healthcare sector 41 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Sep 30 2026 quarter, so far to 160, from total ROA ranking in the second quarter of 2026 at 185.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Sep 30 2026) III. Quarter	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter
Y / Y Total Assets Change	32.94 %	32.24 %	12.24 %	0.09 %	-10.37 %
Y / Y Net Income Change	23.69 %	34.46 %	8.09 %	15.48 %	15.25 %
Net Income (TTM) in million	518	492	460	451	433
Return On Assets (TTM)	24.33 %	24.77 %	24.79 %	25.07 %	24.07 %
MEDP's Total Ranking	# 160	# 185	# 189	# 208	# 219
Total Assets (TTM) in million	2,330	2,078	2,130	1,975	1,753
Seq. Total Assets Change	12.12 %	-2.4 %	7.8 %	12.69 %	11.54 %
Seq. Net Income Change	13.26 %	-2.02 %	-8.33 %	21.59 %	23.13 %

MEDP's 5 Years Annual ROA >> Back to MEDP Management Effectiveness >> Compare MEDP ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 3
Sector	# 42
Overall	# 160

Return On Assets Statistics
High	Average	Low
25.07 %	13.98 %	1.89 %
(Dec 31 2025)		(Mar 31 2017)

Financial Statements
Medpace Holdings Inc 's Assets	$ 2,330 million	MEDP's Balance sheet
Medpace Holdings Inc 's Income	$ 137 million	Quarterly MEDP's Income Statement
MEDP's Income by Division		See MEDP's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	0.09 %	30.3 %	24.64 %	-20.67 %	19.81 %
Total Assets in million	1,975	1,974	1,515	1,215	1,532
Y / Y Net Income Change	11.56 %	42.99 %	15.26 %	34.93 %	25.08 %
Net Income in million	451	404	283	245	182
Annual Return On Assets	22.84 %	20.49 %	18.67 %	20.19 %	11.87 %

MEDP's 5 Years Annual ROA >> Back to MEDP Management Effectiveness >> Compare MEDP ROA to its Competitors

Comment on MEDP's ROA in the fiscal year ending 2025

In the fiscal year 2025 ROA improved to 22.84 % compared to prior year, due to annual net income growth of 11.56 % to $451.12 million, while value of Medpace Holdings Inc 's overall assets grew just by 0.09 % to $1,975.47 million, compared to $1,975.47 a year before.

More Return On Assets Ratios
MEDP's' Return on Assets at Yahoo Finance
Medical Laboratories Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
MEDP's Roa Ratio versus Medical Laboratories Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for MEDP's Competitors
Subscribers only: Roa for Medpace Holdings Inc 's Suppliers
Subscribers only: Return On Assets for MEDP's Customers

You may also want to know
MEDP's Roi	MEDP's Inventory Turnover Ratio	MEDP's Growth Rates	MEDP's Dividend Comparisons
	MEDP's Profitability Ratios	MEDP's Asset Turnover Ratio	MEDP's Dividend Growth
MEDP's Roe	MEDP's Valuation Ratios	MEDP's Financial Strength Ratios	MEDP's Dividend Payout Ratio

Companies with similar Return On Assets at Sep 30 2026, within Healthcare Sector	ROA
Exelixis Inc	63.88 %
Rigel Pharmaceuticals Inc	59.56 %
Alnylam Pharmaceuticals Inc	46.08 %
Ironwood Pharmaceuticals inc	42.53 %
Aurinia Pharmaceuticals Inc	40.63 %
Nurix Therapeutics Inc	38.61 %
Indivior Pharmaceuticals Inc	36.35 %
Rallybio Corporation	34.55 %
Idexx Laboratories Inc	34.05 %
Zevra Therapeutics Inc	26.33 %
Caredx Inc	25.74 %
Medpace Holdings Inc	24.47 %
Acadia Pharmaceuticals Inc	21.60 %
Standard Biotools Inc	21.56 %
Eli Lilly And Company	21.24 %
Iradimed Corporation	20.89 %
Resmed Inc	18.67 %
Alector Inc	18.37 %
Corcept Therapeutics Inc	18.09 %
Chemed Corporation	17.73 %
Halozyme Therapeutics Inc	17.26 %
Pro dex Inc	16.75 %
Denali Therapeutics Inc	16.42 %
Krystal Biotech Inc	15.48 %
West Pharmaceutical Services Inc	15.47 %
Dexcom Inc	15.47 %
Intuitive Surgical Inc	14.71 %
Vertex Pharmaceuticals Inc	14.16 %
Neurocrine Biosciences Inc	13.69 %
Illumina Inc	13.43 %

Date modified: 2026-10-23T06:26:00+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.